INHIBRX BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
INHIBRX BIOSCIENCES, INC. (INBX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$29.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-19
- INHIBRX BIOSCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$29.41M, a 108.30% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $354.39M.
- INHIBRX BIOSCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$50.68M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$29.41M 10-K · filed 2026-03-19 |
| 2024-12-31 | $354.39M 10-K · filed 2026-03-19 |
| 2023-12-31 | -$50.68M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |